cyrilzakka/clinical-trials huggingface dataset:
Comparison of Dry Needling and Thera Gun Treatment on Trapezius Muscle Active Trigger Points.

Comparison of dry needling and Thera Gun on treatment of Active trigger points of trapezius Muscle, pain threshold and Range of motion of neck.

Chronic neck pain related to the myo-facial systems from local muscle fiber contractions referred to "myo-facial trigger points" (MTrPs).MTrPs are highly sensitive spots that lie in the skeletal muscle, and are diagnosed with mechanical pressure, they can also develop as referral pain in a specific pattern. Although MTrPs are found in all muscle groups, they are more prevalent in the upper quarter postural muscles, especially the upper trapezius muscle.

Data will be collected from both gender patients having active trigger points in trapezius muscles. Then patients will be divided randomly into two groups. All patient will be given conventional treatment and then group A will be given treatment with Thera Gun and group B will be given dry needling treatment and then will compare effects of both.

To date, a wide range of physical therapy interventions have been suggested to address MTrPs including manual therapies (massage, stretching, myofascial release), electrotherapy modalities (surface heat, ultrasound, Transcutaneous Electrical Nerve Stimulator and laser therapy) and invasive techniques such as dry needling (DN) but none of study is done on the effectiveness of facial gun in decreasing pain intensity and increasing range of motion and none of study compare the effect of Dry needling with facial gun. So, this study will determine the effect of facial gun on pain intensity and range of motion and compare that effect with dry needling.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with cervical pain due to active trigger points of trapezius muscle
* Numeric Pain Rating Scale\> 3

Exclusion Criteria:

* Any previous history of Trauma or surgery
* Spondylitis
* Carcinoma
* Tuberculosis of spine
* Diagnosed with cervical pain \& stiffness due to disc herniation, radiculopathy or any other cervical malignancy
Prehabilitation for Esophageal Resection Surgery

Consenting patients scheduled for esophageal resection surgery will be randomized to receive standard nutrition counseling (including nutritional supplements as needed) or standard nutrition counseling and exercise 4 weeks before surgery and 8 weeks after surgery.

It is hypothesized that, compared with the group receiving nutrition alone, the addition of physical exercise to nutrition starting before surgery and continuing for 8 weeks after surgery will have a significantly greater impact on functional walking capacity during the prehabilitation period and during the postoperative period, and on the incidence of postoperative pulmonary complications.

A randomized controlled study in patients undergoing esophageal resection for cancer to determine the impact of multimodal prehabilitation on functional exercise capacity and postoperative pulmonary complications. Patients who accept to be enrolled in the study will be randomized to receive either a standard nutritional intervention (including supplements as needed) as per current institution policy or standard nutritional intervention (including supplements as needed) combined with a physical exercise program before and after surgery.

Specific aims

The aims of this research project are the following:

1. To determine the extent in which a multimodal prehabilitation regimen optimizes functional recovery in patients suffering from esophageal cancer and the incidence of postoperative pulmonary complications.
2. To understand further which measures of immediate surgical recovery are sensitive to prehabilitation interventions, and predict change in later outcome measures.

Eligibility Criteria:
Inclusion Criteria:

* 18 and older
* referred electively for resection of malignant esophageal lesion

Exclusion Criteria:

* American Society of Anesthesiologists (ASA) health status class 4-5
* Dementia and psychosis
* Disabling orthopedic and neuromuscular disease
* Severe cardiac abnormalities
* Severe end-organ disease such as cardiac failure (New York Heart Association classes I-IV)
* COPD
* renal failure (creatinine \> 1.5 mg/dl, and hepatic failure ALT and AST \>50% over the normal range)
* Morbid obesity (BMI \>30)
* Anemia (hematocrit \< 30 %, haemoglobin \<10g/dl, albumin \< 25mg/dl)
Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents

The primary objective is to estimate the Complete Response rate of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) compared to cisplatin-5-fluorouracil (CF) in the Induction treatment of Nasopharyngeal Carcinoma (NPC).

The secondary objectives are to determine:

* the safety of TCF in comparison to CF after induction treatment of NPC,
* the pharmacokinetics of docetaxel when added to CF,
* the Overall Response rate of TCF and CF on completion of induction and consolidation (chemo-radiotherapy) treatment of NPC, and to compare overall survival between TCF and CF.

Planned treatment duration:

* induction period: 9 weeks of induction treatment
* consolidation period: 9 weeks of chemoradiation treatment.

The consolidation treatment was the same for all participants: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Histological diagnosis of nasopharyngeal carcinoma World Health Organization (WHO) type II or III
* Children and adolescents newly diagnosed with Stage IIB-IV NPC with measurable disease, who are \>1 month to ≤21 years of age at the time of diagnosis. In France, participants must be ≥1 year to ≤21 years of age at the time of diagnosis

Exclusion Criteria:

* Participants with short life expectancy
* Prior chemotherapy or radiotherapy to the nasopharynx or neck for the treatment of nasopharyngeal carcinoma
* Inadequate renal function evidenced by unacceptable laboratory results

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Fentanyl as an Adjuvant to Peribulbar Block in Buckle or Squint Surgeries

The use of fentanyl as an adjuvant to local anesthetic mixture in many regional blocks. It was effective when used in peribulbar block in cataract and vitreoretinal surgeries.

Our study will assess its efficacy in abolishing pain during muscle traction which is usually a complain for many patients a reason to use systemic opioid intra operatively or even general anesthesia

After the patient enters the OR room, an intravenous cannula will be introduced, pulse oximeter, ECG and NIBP monitors will be connected.

Nasal oxygen cannula connected; 10 ml of local anesthetic mixture is injected depending on the group the patient is allocated.

Increments of intravenous intravenous fentanyl and midazolam will be given if patient experienced unbearable pain.

All patient received peribulbar block by an experienced anesthesiologist, both patient and anesthesiologist were blinded to the drug mixture used.

Each patient received 10 ml of the anesthetic mixture according to his/ her group.

The patient was asked to fix his eyes looking straight forward toward the ceiling while lying in a supine position. A 10 ml syringe with a 25G needle was used for the local anesthetic injection. After negative aspiration, the first 5 ml were slowly injected at the junction of the lateral one third and medial two thirds of the inferior orbital margin with the bevel directed towards the equator of the eye ball parallel to the orbital floor and the other 5 ml were given between the caruncle and the medial canthus. Intermittent gentle massage was applied for 10 minutes. After satisfactory sensory and motor block, oxygen 3 L/min was delivered through a nasal cannula to the patient. Surgery was then allowed to proceed.

Eligibility Criteria:
Inclusion Criteria:

* ASA 1, 2 \& 3
* Age 18 to 70
* Patients undergoing squint or buckle surgeries

Exclusion Criteria:

* Sensitivity to any drug used in this study
* Refusal of the patient for peribulbar block
* Redo squint surgeries or previous buckle insertion
* High axial length if documented
* mentally retarded patients and
* failure of proper communication as in deafness,
* coagulation abnormalities (INR\>1.4),
* infection at the injection site
The Lira Pump Trial

A randomized placebo-controlled clinical trial investigating the effects of Liraglutide as an add-on to intensive insulin therapy in overweight insulin pump treated type 1 diabetes patients in suboptimal glycemic control.


Eligibility Criteria:
Inclusion Criteria:

* Type 1 diabetes ≥ 1 year
* BMI \> 25 kg/m2
* Insulin pump ≥ 1 year
* HbA1c \> 58 mmol/mol
* Use of carbohydrate counting and the insulin pump bolus calculator

Exclusion Criteria:

* Gastroparesis
* Impaired renal function (eGFR \< 60 ml/min/1.73m2)
* Liver disease with ALAT \> 2.5 times the upper limit of the reference interval
* Acute or chronic pancreatitis or history of chronic pancreatitis or idiopathic acute pancreatitis
* Inflammatory bowel disease
* History of cancer (except basal cell skin cancer) which in the investigators opinion could interfere with the results of the trial, or cancer during the past 5 years
* Thyroid adenoma
* Subjects with personal or family history of MTC or MEN2
* Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start
* Known or suspected alcohol or drug abuse
* Other concomitant medical or psychological condition that according to the investigator's assessment makes the patient unsuitable for study participation
* Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods.
* Simultaneous participation in any other clinical intervention trial
* Known or suspected hypersensitivity to Liraglutide
* Inability to understand the patient information and to give informed consent
* Acute treatment required proliferative retinopathy or maculopathy (macular oedema)
* Any Cardiac disorder which in the investigators opinion could interfere with the safety and results of the trial.
Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme

RATIONALE: Current therapies for Glioblastoma Multiforme provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of brain tumors.

PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on adults (≥ 18 years of age) with newly diagnosed Glioblastoma Multiforme.

OVERVIEW: This is a single arm, open-label study in which adults (≥ 18 years of age) with newly diagnosed Glioblastoma Multiforme receive gradually escalating doses of intravenous Antineoplaston therapy (Atengenal + Astugenal) until the maximum tolerated dose is reached. Treatment continues for at least 12 months in the absence of disease progression or unacceptable toxicity.

OBJECTIVES:

* To determine the efficacy of Antineoplaston therapy in adults (≥ 18 years of age) with newly diagnosed Glioblastoma Multiforme, as measured by an objective response to therapy (complete response, partial response or stable disease).
* To determine the safety and tolerance of Antineoplaston therapy in adults (≥ 18 years of age) with newly diagnosed Glioblastoma Multiforme.
* To determine objective response, tumor size is measured utilizing MRI scans, which are performed every 8 weeks for the first two years, every 3 months for the third and fourth years, every 6 months for the 5th and sixth years, and annually thereafter.

PROJECTED ACCRUAL: A total of 20-40 patients will be accrued to this study.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Histologically or cytologically confirmed Glioblastoma Multiforme
* Subtotal resection or biopsy only of tumor
* Measurable tumor by MRI scan performed within two weeks prior to study entry
* Tumor must be at least 5 mm
* No brain stem tumor

PATIENT CHARACTERISTICS:

Age:

* 18 and over

Performance status:

* Karnofsky 60-100%

Life expectancy:

* More than 4 months

Hematopoietic:

* WBC at least 1,500/mm\^3
* Platelet count at least 50,000/mm\^3
* Hemoglobin at least 10 g/dL

Hepatic:

* No hepatic failure
* Bilirubin no greater than 2.5 mg/dL
* SGOT and SGPT no greater than 5 times upper limit of normal

Renal:

* Creatinine no greater than 2.5 mg/dL
* No history of renal conditions that would contraindicate high dosages of sodium

Cardiovascular:

* No uncontrolled hypertension

Other:

* Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* No prior immunotherapy
* No concurrent immunomodulatory agents

Chemotherapy:

* No prior chemotherapy
* No concurrent antineoplastic agents

Endocrine therapy:

* Concurrent corticosteroids for cerebral edema allowed

Radiotherapy:

* No prior radiotherapy

Surgery:

* See Disease Characteristics
* Recovered from any prior surgery
Impact of a Decision Aid Regarding Natural Health Products for Menopausal Symptoms

The aim of this study is to assess the impact of a patient decision aid regarding natural health products for menopausal symptoms on decisional conflict, knowledge and persistence for an option of women aged 45-64 years old. We are expecting a decrease in decisional conflict and an improvement on knowledge level. We are also expecting an intention to use the decision aid in the future and to discuss with the physician or pharmacist about the use, or the intention to use natural health products.

Health decision making is a process known to be difficult, specially in uncertainty context. Because of a lack of evidence, natural health products field remains uncertain. Decision aids (or decision support interventions) have been elaborated in the past for several health decisions and previous studies showed that they seem to be effective on reducing decisional conflict. Following a needs assessment with 40 women and 15 key informants, we developed a decision aid tool specific to the context of natural health products for menopause. In this study, we will assess its impact on decisional conflict, knowledge, persistence for an option, intention to use for a future decision in the same area, and intention to disclose use of natural health products to health professionals.

Comparison: An existing general information brochure on menopause compared to a decision aid tool that we developed based on the Ottawa Decision Support Framework.

Eligibility Criteria:
Inclusion Criteria:

Women :

* between 45 and 64 years old
* reporting suffering from menopausal symptoms
* considering the use of natural health products for menopausal symptoms
* able to read, write, and understand french at a grade 8 level
* able to give an informed consent for her participation to the study

Exclusion Criteria:

* manager and/or owner of a natural health products store,a pharmacy and/or a pharmaceutical company
* person with close relationships with one or many collaborators of this study
* reporting suffering from symptoms with no precise diagnosis
IL-32 Levels in Patients With Chronic Periodontitis

Interleukin-32 (IL-32) is a recently described cytokine that is a strong inducer of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α. A previous report have reported that Porphyromonas gingivalis-derived LPS significantly up-regulated IL-32 expression compared with the unstimulated cells in monocytes (THP-1 cells). They suggested that IL-32 may contribute to the pathogenesis of periodontal disease. In the present study the investigators hypothesized that IL-32 levels may increase in the gingival crevicular fluid (GCF) and saliva of patients with chronic periodontitis compared with healthy controls and these levels may decrease together with treatment.

The purpose of this study was to investigate IL-32 levels in the GCF and saliva of patients with chronic periodontitis and to evaluate changes after nonsurgical periodontal therapy.

Twenty-seven CP and 27 periodontally healthy controls were enrolled in this study. Periodontitis patients received nonsurgical periodontal treatment. GCF and saliva sampling and clinical periodontal parameters were assessed before and a month after treatment. IL-32, IL-10 and TNF-α levels in GCF and saliva were measured by enzyme-linked immunosorbent assay.

Unstimulated salivary samples were collected using standard techniques. About 2 mL whole saliva was collected in disposable tubes and centrifuged immediately to remove cell debris (10,000 g x 10 minutes). The supernatants (50µL each) were stored at -40C until analyzed. GCF samples were collected from a mesio-buccal and disto-palatal site on each tooth. In the CP group, the samples were obtained from patients at areas with ≥5 mm CAL, ≥6 mm PD and ≥30% bone loss. In the healthy group, GCF samples were collected from teeth exhibiting PD\<3 mm without CAL and BOP. The area was isolated with cotton rolls, saliva contamination elimination was ensured, and it was slightly air dried. GCF was sampled with paper strips. Paper strips were placed into the crevice until mild resistance was felt (intracrevicular method) and left in the position for 30 seconds. Strips contaminated with blood or saliva were discarded. Each sampled strip was placed into a 400µl eppendorf centrifuge tube and stored at -40C until analyzed.

Eligibility Criteria:
Inclusion Criteria:

* all subjects in the study were possess of at least 20 teeth excluding third molars.

Exclusion Criteria:

* agressive periodontitis,
* periapical pathologies,
* excessive forces including mechanical forces caused by orthodontic forces and occlusal forces;
* presence of systemic diseases;
* administration of non-steroidal and anti-inflammatory drugs or antibiotic therapies within the previous 6 months;
* need for antibiotic prophylaxis for dental treatment and having received non-surgical periodontal treatment within the past 6 months or surgical periodontal treatment within the past 12 months;
* allergy or sensitivity to any drug,
* pregnancy,
* lactation, and
* current and former use of tobacco.
Building Individual and Community Resilience Through Nature-based Therapies - Case Study 8 Nature for All

The aim of this randomized controlled trial is to test if digital engagement instructions (a nature guide APP) can enhance the nature connection and provide positive health outcomes for individuals with mobility disabilities.

The study has an active control group, that will have the same nature exposure without the guidance of the APP. 124 participants will be randomized to either the intervention group or the control group.

The intervention consists of two parts:

Intervention day 1: The intervention starts for both the 'intervention group' and the 'control group' in the Hoersholm arboretum, which contain Denmark's largest collection of different trees and shrubs. The intervention group will listen to the 'intervention APP' during a tour with three stops along a trail in the arboretum. The active control group will take the same tour but does not have access to the 'intervention APP'.

4 week intervention: During the following 4 weeks the participants will be encouraged to visit nature for 120 minutes in total per week on their own. The intervention group will still be encouraged to use the APP during the nature visits.

See protocol

Eligibility Criteria:
Inclusion Criteria:

* Not being able to walk at all or be able to walk short distances (ICF 2017: d4500, walking short distances; walking for less than a kilometer, such as walking around rooms or hallways, within a building or for short distances outside)
* All types of assistive devices, including e.g. scooters, walkers, and canes. Also service dogs and personal carers are included.
* Adults (+18 years)
* All genders
* All educational levels
* All religious affiliations
* All types of marital status
* All types of households
* All types of employment and income

Exclusion Criteria:

* - Do not understand Danish (APP, questionnaires and interviews in Danish)
* Physically not able to use a smartphone with touch screen, by themselves or with the help of a personal carer
* Participating in mindfulness program during intervention (intervention day 1 and 4-week intervention period)
* Cognitive limitations (difficulties in understanding and using information from APP, understanding and responding to questionnaires and interviews.)
* Known drug or alcohol abuse
* Diagnosed epilepsy
F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer

Until today no current diagnostic tool exists to identify an early objective response when patients with castration-resistant prostate cancer were treated by abiraterone acetate or enzalutamide. According to the Prostate Cancer Working Group, the investigators have to wait 12 weeks before the first evaluation. To know soon that the treatment is effective will be decisive for the oncologist, even more in palliative situation where second effects can't be imposed to patients.

In post-docetaxel, the F-choline PET-CT could be used to assess the response of this new therapy. Moreover, the investigators suppose that we can assess an early stage if there is an objective therapeutic response, at 6 weeks of treatment, in order to avoid unnecessarily and expansive treatment.

The aim of this study is to assess if it is possible to determine early (6 weeks of treatment)if a F-choline PET-CT could predict the response to abiraterone acetate or enzalutamide in post-docetaxel.


Eligibility Criteria:
Inclusion Criteria:

* Age \> 18 years
* Eastern Cooperative Oncology Group (ECOG)performance status score of 2 or less
* Histologically or cytologically confirmed adenocarcinoma prostate cancer without neuroendocrine component (component with minority neuroendocrine) or small cell, or neuroendocrine cells or small minority component prostate who underwent surgical or medical castration
* Disease progression during or after a docetaxel-based chemotherapy
* serum testosterone level of 50 ng per deciliter or less (≤2.0 nmol per liter)
* Biologic criteria :
* platelets ≥ 100 000/μl,
* Creatinine \<1.5 x upper limit or creatinine clearance ≥ 60 ml / min,
* Serum potassium ≥ 3.5 mmol / l,
* Bilirubin \<1.5 x upper limit of normal (ULN)
* hemoglobin ≥ 9.0 g / dl without any transfusion.

Exclusion Criteria:

* abnormal aminotransferase levels (levels of aspartate aminotransferase or alanine aminotransferase that were ≥2.5 times the upper level of the normal range; patients with known liver metastasis who had levels of aspartate aminotransferase or alanine aminotransferase that were ≤5 times the upper level of the normal range were eligible to participate
* previous therapy with ketoconazole
* serious coexisting nonmalignant disease :
* active or symptomatic viral hepatitis or chronic liver disease,
* uncontrolled hypertension,
* a history of pituitary or adrenal dysfunction,
* clinically significant heart disease
Treatment of Refractory Auditory Verbal Hallucinations With tDCS in Schizophrenia

The purpose of this study is to exploratively evaluate the efficacy and safety of transcranial direct current stimulation (tDCS) in patients with schizophrenia who experience persistent auditory verbal hallucinations after adequate antipsychotics therapy for over three months.


Eligibility Criteria:
Inclusion Criteria:

* Patients with schizophrenia by the Diagnostic and Statistical Manual of Mental Disorders, Fourth edition, Text Revision (DSM-IV-TR)
* Presence of auditory hallucination after three months' trial of antipsychotics of adequate dose
* The Hamilton Program for Schizophrenia Voices Questionnaire (HPSVQ) score is at least 8

Exclusion Criteria:

* Significant brain pathology including head trauma, seizure, meningitis
* Intellectual disability (IQ \< 70)
* Severe personality disorder
* Substance use disorder (except nicotine)
* Severe medical illness
* Disability in the sensory organs
* Pregnancy